Review the Lidocaine / Tetracaine source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Emerald lists a 23/7 entry with 300 g, without explicit percentage units, and a separate 30 g cream without strengths. Optimal lists 23% / 10% with 60 mL. These are separate specifications; no strength is transferred between entries.
Listed package: 30 g / 300 g / 60 mL — separate entries. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing3 source entries. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Lidocaine/Tetracaine 23/7 300gDo not infer percentage units or dosage form; obtain complete specification | 23/7 — source units not explicit | 300 g |
| Lidocaine/Tetracaine cream 30gCream explicitly named; do not import strengths from another listing | Strengths not supplied | 30 g |
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Lidocaine/Tetracaine 23%/10%Dosage form not explicit; confirm component forms, vehicle and intended route | 23% / 10% — confirm percentage basis | 60 mL |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
A shared ingredient pair does not establish equivalent formulation, concentration or dosage form. Do not convert package mass to volume or infer missing units.
FDA’s NASEM summary identifies limited evidence and safety-data gaps for compounded topical pain creams. That review does not validate these exact source preparations. Obtain complete ingredient forms, percentage basis, dosage form, route and preparation-specific safety information. FDA: NASEM compounded topical pain cream assessment
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. For a commercially manufactured product, verify its exact identity and current labeling separately. FDA: compounded drug information
Sources checked October 20, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
The source does not establish that. The 30 g cream lists no strengths, and the separate 23/7 entry does not explicitly state its units. Ask Emerald to clarify both preparations independently.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.